132 related articles for article (PubMed ID: 10321740)
1. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity.
Zhu J; Jiang J; Zhou W; Zhu K; Chen X
Oncogene; 1999 Mar; 18(12):2149-55. PubMed ID: 10321740
[TBL] [Abstract][Full Text] [Related]
2. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
3. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Baptiste N; Friedlander P; Chen X; Prives C
Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
[TBL] [Abstract][Full Text] [Related]
4. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
5. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Burns TF; Bernhard EJ; El-Deiry WS
Oncogene; 2001 Aug; 20(34):4601-12. PubMed ID: 11498783
[TBL] [Abstract][Full Text] [Related]
6. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions.
Edwards SJ; Hananeia L; Eccles MR; Zhang YF; Braithwaite AW
Oncogene; 2003 Jul; 22(29):4517-23. PubMed ID: 12881708
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
8. Germ-line-derived hinge domain p53 mutants have lost apoptotic but not cell cycle arrest functions.
Aurelio ON; Cajot JF; Hua ML; Khwaja Z; Stanbridge EJ
Cancer Res; 1998 May; 58(10):2190-5. PubMed ID: 9605765
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional regulation and induction of apoptosis: implications for the use of monomeric p53 variants in gene therapy.
Merkle C; Fritsche M; Mundt M; Jähne R; Groner B
Gene Ther; 1998 Dec; 5(12):1631-41. PubMed ID: 10023442
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.
Roth J; Koch P; Contente A; Dobbelstein M
Oncogene; 2000 Mar; 19(14):1834-42. PubMed ID: 10777217
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
12. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis.
Nagashima M; Shiseki M; Pedeux RM; Okamura S; Kitahama-Shiseki M; Miura K; Yokota J; Harris CC
Oncogene; 2003 Jan; 22(3):343-50. PubMed ID: 12545155
[TBL] [Abstract][Full Text] [Related]
13. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.
Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D
Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310
[TBL] [Abstract][Full Text] [Related]
14. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
Venot C; Maratrat M; Dureuil C; Conseiller E; Bracco L; Debussche L
EMBO J; 1998 Aug; 17(16):4668-79. PubMed ID: 9707426
[TBL] [Abstract][Full Text] [Related]
15. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
Mendoza-Rodríguez CA; Cerbón MA
Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
17. Activation of p53 DNA binding activity by point mutation.
Marston NJ; Ludwig RL; Vousden KH
Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
[TBL] [Abstract][Full Text] [Related]
18. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro.
Lai PB; Chi TY; Chen GG
Apoptosis; 2007 Feb; 12(2):387-93. PubMed ID: 17191126
[TBL] [Abstract][Full Text] [Related]
19. Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant.
Lassus P; Bertrand C; Zugasti O; Chambon JP; Soussi T; Mathieu-Mahul D; Hibner U
Oncogene; 1999 Aug; 18(33):4699-709. PubMed ID: 10467417
[TBL] [Abstract][Full Text] [Related]
20. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.
Mirza A; Wu Q; Wang L; McClanahan T; Bishop WR; Gheyas F; Ding W; Hutchins B; Hockenberry T; Kirschmeier P; Greene JR; Liu S
Oncogene; 2003 Jun; 22(23):3645-54. PubMed ID: 12789273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
